Loading clinical trials...
Loading clinical trials...
A Single-arm, Open-label Phase I Study of CAR-T-19 (Anti CD19 scFv Chimeric Antigen Receptor T) Cells for Patients With CD19-positive Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Under The Age of 25
Conditions
Interventions
CAR-T-19 Cells
Locations
1
China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Start Date
February 25, 2021
Primary Completion Date
July 15, 2022
Completion Date
September 16, 2024
Last Updated
March 8, 2022
Lead Sponsor
Chinese PLA General Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions